Datapharm partners with Doctor Evidence to bring its UK dataset to US clients via DOC™ Label

Share Article

Datapharm, a leading provider of medicine information in Europe, is pleased to announce the finalization of an agreement with Doctor Evidence, LLC., granting access to their database of over 5,600 drug labels from the United Kingdom (UK) and European Union (EU).

Datapharm, a UK-based, not-for-profit organization provides trusted, credible information about medicines to major stakeholders in the healthcare industry, and houses its collection of data in the electronic Medicines Compendium (eMC) database, which includes Summaries of Product Characteristics (SPCs) and Patient Information Leaflets (PILs), the latter being the European equivalent of FDA drug labels. This agreement will provide Doctor Evidence with access to both SPCs and PILs from the eMC database.

“Outside of the US, Datapharm represents one of the most efficient stores of centralized drug label data,” said Bob Battista, co-founder and Chief Executive Officer of Doctor Evidence. “This combination of the US data and the UK data in our DOC Label solution will address a critical need in the regulatory affairs labeling market to enable users to query and compare across US package inserts and UK SPCs in a single session. Our clients have been asking us to provide one, unified drug label compare functionality to enable them to better assess their comprehensive benefit risk management activities.”

The partnership between Datapharm and Doctor Evidence will enable significant expansion of DOC™ Label, Doctor Evidence's premier solution for clinical label management, through the inclusion of data from the European market. DOC™ Label functions as an all-in-one repository and search tool for approved drug labels, with features that include the ability to search DOC™ Label's internal database using numerous different parameters as well as to identify version changes across different releases of the same drug label over time. The aim of the tool is to reduce or remove inefficiencies created by the manual completion of the everyday tasks required of users in regulatory affairs, competitive intelligence, product planning and labeling departments.

The current iteration of DOC™ Label contains almost 50,000 FDA drug labels from the FDA drug label database. The completion of the deal with Datapharm will provide Doctor Evidence with ongoing access to Datapharm’s database of over 5,600 SPC labels, covering over ninety percent of commonly prescribed drugs licensed in the United Kingdom. Twelve percent of the SPCs have an EU centralized license while the remaining have a national UK license. The volume of these labels has been growing by more than ten percent annually in recent years.

“This partnership represents a major opportunity for the pharmaceutical industry to realize some of the value that it has already established through the creation of the eMC database,” explained Dr Peter Carroll, Datapharm’s Director of Medicines Information. “Datapharm is delighted to have this opportunity to support a number of key business processes for the US affiliates of its UK member companies. Incorporating the eMC database into the Doctor Evidence platform will bring important new data sets to the fingertips of those in healthcare who need it most in an intuitive and easy to use format.”

About Doctor Evidence, LLC

Doctor Evidence is a specialty software platform and services company aimed to assist stakeholders across the healthcare ecosystem to make and inform clinical and business decisions with the most relevant medical evidence. The Doctor Evidence methodology uses a Digital Outcome Conversion (DOC™) approach of taking data from published clinical studies, FDA drug labels, and epidemiological databases to transform static data into reusable, dynamic relational databases. Our software platform empowers both public and private sector clients to identify the most relevant literature and conduct ready analyses with the highest level of transparency available for today's evidence-based medicine methodological standards, in the pursuit of reducing healthcare costs while increasing the quality of patient outcomes.

Doctor Evidence serves decision-makers in two large addressable market segments, Medical Manufacturers and Healthcare Providers, for the ultimate wellbeing of patients. Doctor Evidence is helping to transform the healthcare ecosystem by identify the most efficacious and safe medical treatment on a comparative effectiveness basis, including related economic costs and total-cost-of-care analysis.

About Datapharm

Datapharm is a not-for-profit member’s organization whose mission is to improve public health and safety by providing up-to-date, accurate and comprehensive information about medicines to healthcare professionals, medicine users, carers and the general public. Founded in 1977, the company serves over 200 pharmaceutical company members, which include companies manufacturing branded, generic and consumer medicines. Datapharm serves the wider healthcare ecosystem working closely with a wide range of healthcare organizations to provide high quality information about medicines. These include the NHS, the Department of Health, and the Medicines and Healthcare Products Regulatory Agency (MHRA).

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Peter Carroll
Visit website